^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Mucosal Melanoma

    Related cancers:
    2d
    Efficacy and Safety of DNV3 (a Lymphocyte-activation Gene 3-blocking Antibody) Combined With Toripalimab and Chemotherapy in Advanced Melanoma: An Open-label, Single-arm Clinical Trial. (PubMed, MedComm (2020))
    This study evaluated a novel combination of DNV3 (anti-LAG-3), toripalimab (anti-PD-1), and chemotherapy (nab-paclitaxel/cisplatin) in 27 Asian patients with unresectable or metastatic melanoma (77.8% [21/27] previously treated with anti-PD-[L]1 and 22.2% [6/27] treatment-naïve mucosal melanoma; subtypes: 13 mucosal, 6 acral, 5 cutaneous, and 3 of unknown primary origin). Therefore, the combination of LAG-3/PD-1 blockade and chemotherapy demonstrated promising efficacy, notably in treatment-naïve mucosal melanoma with liver metastases. (Chinese Clinical Trial Registry number, ChiCTR2400079543).
    Journal
    |
    LAG3 (Lymphocyte Activating 3)
    |
    cisplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    2d
    (BLOOM): Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy (clinicaltrials.gov)
    P1/2, N=55, Not yet recruiting, University of Chicago | Initiation date: Jan 2026 --> Dec 2026
    Trial initiation date
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    2d
    MC2TCR: MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Erasmus Medical Center | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    BRAF (B-raf proto-oncogene)
    |
    azacitidine
    3d
    Comparison of [18F]PFPN and [18F]FDG PET in mucosal melanoma: diagnostic performance, staging impact, and correlation with molecular markers. (PubMed, Clin Cancer Res)
    [18F]PFPN PET outperforms [18F]FDG PET in lesion detection and clinical staging in mucosal melanoma, especially for liver and bone metastases. Its association with melanin differentiation markers may support its use in personalized imaging strategies.
    Journal
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • SOX10 (SRY-Box 10)
    |
    BRAF mutation • NRAS mutation
    3d
    SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (clinicaltrials.gov)
    P3, N=1301, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • Intron A (interferon α-2b) • Bioferon (interferon alpha 2b)
    9d
    Primary Malignant Melanoma of the Nasolacrimal Duct Presenting Without Hemolacria: A Case Report and Literature Review. (PubMed, Curr Oncol)
    Early cross-sectional imaging and biopsy are essential for accurate diagnosis. Furthermore, this case suggests that a multimodal approach combining wide surgical excision and adjuvant radiotherapy may contribute to durable local control in selected patients.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    10d
    Retrospective Study of Trametinib in Patients With Advanced NF1-Mutant Melanoma. (PubMed, JCO Precis Oncol)
    Despite the small number of patients in our study, our findings suggest the promising activity of trametinib in patients with NF1-mutant melanoma, supporting a rationale for prospective studies of MEK inhibitor therapy.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    NF1 (Neurofibromin 1)
    |
    Mekinist (trametinib)
    13d
    Establishment and characterization of a cell line (OS-MM) originating from a human malignant melanoma of the oral mucosa. (PubMed, In Vitro Cell Dev Biol Anim)
    A genetic analysis of OS-MM cells revealed the absence of BRAF and NRAS mutations; however, a GNAS mutation was identified. The OS-MM cell line should contribute to advances in personalized therapy for malignant oral mucosal melanoma.
    Preclinical • Journal
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • GNAS (GNAS Complex Locus)
    |
    BRAF mutation • NRAS mutation
    15d
    Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) (clinicaltrials.gov)
    P2, N=494, Recruiting, Melanoma Institute Australia | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    16d
    Axitinib and Nivolumab for the Treatment of Mucosal Melanoma (clinicaltrials.gov)
    P2, N=20, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • axitinib
    17d
    UC-IMM-2509/2510: NEOREM/NEO-1 - NEOREM: Neo-adjuvant Immunotherapy Master Trial for Localized Cancers / NEO-1: Neo-adjuvant immunotherapy in patients with localized melanoma (2025-522127-95-00)
    P1/2, N=50, Recruiting, Unicancer
    New P1/2 trial
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    23d
    NEOREM-NEO-1: Neo-adjuvant Immunotherapy in Patients With Localized Melanoma (clinicaltrials.gov)
    P2, N=50, Recruiting, UNICANCER | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)